European Neuropsychopharmacology
Volume 20, Issue 6 , Pages 414-420 , June 2010

A coding variant of the novel serotonin receptor subunit 5-HT3E influences sustained attention in schizophrenia patients

  • Leonhard Lennertz

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
    • ,
  • Michael Wagner

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
    • ,
  • Ingo Frommann

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
    • ,
  • Svenja Schulze-Rauschenbach

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
    • ,
  • Anna Schuhmacher

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
    • ,
  • Kai-Uwe Kühn

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
    • ,
  • Ralf Pukrop

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany
    • ,
  • Joachim Klosterkötter

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany
    • ,
  • Wolfgang Wölwer

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Düsseldorf, Düsseldorf, Germany
    • ,
  • Wolfgang Gaebel

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Düsseldorf, Düsseldorf, Germany
    • ,
  • Marcella Rietschel

      Affiliations

    • Central Institute of Mental Health, Mannheim, Germany
    • ,
  • Heinz Häfner

      Affiliations

    • Central Institute of Mental Health, Mannheim, Germany
    • ,
  • Wolfgang Maier

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
    • ,
  • Rainald Mössner

      Affiliations

    • Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
    • Corresponding Author InformationCorresponding author. Department of Psychiatry and Psychotherapy, University of Bonn, Sigmund-Freud-Straße 25, DE-53105 Bonn, Germany. Tel.: +49 228 287 1939; fax: +49 228 287 22617.

Received 5 November 2009 ,Accepted 26 February 2010.

References 

  1. Adler LE, Cawthra EM, Donovan KA, Harris JG, Nagamoto HT, Olincy A, et al. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am. J. Psychiatry. 2005;162:386–388
  2. Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, et al. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr. Res. 2009;107:206–212
  3. APA . Diagnostic and Statistical Manual of Mental Disorders. 4th ed.. Washington, DC: American Psychiatric Association; 1994;
  4. Barnes NM, Hales TG, Lummis SC, Peters JA. The 5-HT3 receptor—the relationship between structure and function. Neuropharmacology. 2009;56:273–284
  5. Bertolino A, Blasi G. The genetics of schizophrenia. Neuroscience. 2009;
  6. Bloom FE, Morales M. The central 5-HT3 receptor in CNS disorders. Neurochem. Res. 1998;23:653–659
  7. Bove EA. Cognitive performance and basic symptoms in first-degree relatives of schizophrenic patients. Compr. Psychiatry. 2008;49:321–329
  8. Braff DL, Freedman R, Schork NJ, Gottesman II. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr. Bull. 2007;33:21–32
  9. Chen WJ, Faraone SV. Sustained attention deficits as markers of genetic susceptibility to schizophrenia. Am. J. Med. Genet. 2000;97:52–57
  10. Chen WJ, Hsiao CK, Hsiao LL, Hwu HG. Performance of the Continuous Performance Test among community samples. Schizophr. Bull. 1998;24:163–174
  11. Cornblatt BA, Malhotra AK. Impaired attention as an endophenotype for molecular genetic studies of schizophrenia. Am. J. Med. Genet. 2001;105:11–15
  12. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. 1988;26:223–238
  13. Cullum CM, Harris JG, Waldo MC, Smernoff E, Madison A, Nagamoto HT, et al. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr. Res. 1993;10:131–141
  14. Erwin RJ, Turetsky BI, Moberg P, Gur RC, Gur RE. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr. Res. 1998;33:157–167
  15. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry. 2003;160:636–645
  16. Gur RE, Calkins ME, Gur RC, Horan WP, Nuechterlein KH, Seidman LJ, et al. The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr. Bull. 2007;33:49–68
  17. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426–445
  18. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 2002;71:533–554
  19. Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H, et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr. Res. 2005;76:67–72
  20. Leboyer M, Bellivier F, Nosten-Bertrand M, Jouvent R, Pauls D, Mallet J. Psychiatric genetics: search for phenotypes. Trends Neurosci. 1998;21:102–105
  21. Lehrl S, Merz J, Burkhard G, Fischer S. Mehrfachwahl-Wortschatz-Intelligenztest. Göttingen: Hogrefe; 1999;
  22. Levkovitz Y, Arnest G, Mendlovic S, Treves I, Fennig S. The effect of ondansetron on memory in schizophrenic patients. Brain Res. Bull. 2005;65:291–295
  23. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009;23:315–336
  24. Niesler B, Frank B, Kapeller J, Rappold GA. Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene. 2003;310:101–111
  25. Niesler B, Kapeller J, Hammer C, Rappold G. Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics. 2008;9:501–504
  26. Niesler B, Walstab J, Combrink S, Moller D, Kapeller J, Rietdorf J, et al. Characterization of the novel human serotonin receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E. Mol. Pharmacol. 2007;72:8–17
  27. Rehnström K, Ylisaukko-oja T, Nummela I, Ellonen P, Kempas E, Vanhala R, et al. Allelic variants in HTR3C show association with autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009;150B:741–746
  28. Riley B, Kendler KS. Molecular genetic studies of schizophrenia. Eur. J. Hum. Genet. 2006;14:669–680
  29. Schuhmacher, A., Mössner, R., Quednow, B.B., Kühn, K.-U., Wagner, M., Cvetanovska, G., Rujescu, D., Zill, P., Möller, H.-J., Rietschel, M., Franke, P., Wölwer, W., Gaebel, W., Maier, W., 2009. Influence of 5-HT3 receptor subunit genes 5-HT3A, B, C, D, E on treatment response to antipsychotics in schizophrenia. Pharmacogenetics and Genomics. doi:10.1097/FPC.0b013e3283313296.
  30. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009;460:753–757
  31. Sitskoorn MM, Aleman A, Ebisch SJ, Appels MC, Kahn RS. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr. Res. 2004;71:285–295
  32. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460:744–747
  33. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry. 2003;60:1187–1192
  34. Terry AV, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav. Brain Res. 2008;195:30–38
  35. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr. Bull. 2007;33:69–94
  36. Ücök A, Alpsan H, Cakir S, Saruhan-Direskeneli G. Association of a serotonin receptor 2A gene polymorphism with cognitive functions in patients with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007;144B:704–707
  37. Walderhaug E, Landro NI, Magnusson A. A synergic effect between lowered serotonin and novel situations on impulsivity measured by CPT. J. Clin. Exp. Neuropsychol. 2008;30:204–211
  38. Walderhaug E, Lunde H, Nordvik JE, Landro NI, Refsum H, Magnusson A. Lowering of serotonin by rapid tryptophan depletion increases impulsiveness in normal individuals. Psychopharmacology (Berl). 2002;164:385–391
  39. Wang Q, Chan R, Sun J, Yao J, Deng W, Sun X, et al. Reaction time of the Continuous Performance Test is an endophenotypic marker for schizophrenia: a study of first-episode neuroleptic-naive schizophrenia, their non-psychotic first-degree relatives and healthy population controls. Schizophr. Res. 2007;89:293–298
  40. WHO . International Classification of Disease. World Health Organisation, Geneva, Switzerland: Tenth Revision; 1992;
  41. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005;8:457–472
  42. Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr. Res. 2006;88:102–110

PII: S0924-977X(10)00045-3

doi: 10.1016/j.euroneuro.2010.02.012

European Neuropsychopharmacology
Volume 20, Issue 6 , Pages 414-420 , June 2010

Article Tools

* Image Usage & Resolution